Genome Editing Market Size, Share, Growth Analysis, By Technology((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease), By Delivery Method(Ex-vivo, In-vivo), By Application(Genetic Engineering [Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others]), By Mode(Contract, In-house), By End-Use(Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations), By Region - Industry Forecast 2024-2031

North America is dominated the genome editing market, accounting for 47.81% in 2023 due to rising investments in R&D of gene editing technologies. Several biotechnologies and the pharmaceutical companies operating in the genome editing technology are estimated to remain dominant over the forecast period. Availability of strong research infrastructure, rise in genetically modified crops, high genetic diseases inherited diseases are common. In other words, the number of licenses issued by U.S-based firms. Increased supply has also accelerated the development of genome editing tools in the country, leading to positive market growth.

Asia Pacific is expected to witness fastest growth at 18.75% CAGR between 2024 and 2030. Also attracting investment and finance from domestic companies providing gene editing products and services. For example, in April 2021, GeneScript launched a Research-Grade Lentiviral Vector Packaging Service for drug discovery, cell line manufacturing and gene editing. The company is developing initiatives to promote genome engineering services such as CRISPR services and gene services. The growth of the nearby market is anticipated to be driven by the increasing demand for for gene modifying technology and growing incidence of genetic sicknesses and illnesses in countries such as India and Australia.